Back to top
more

Fulcrum Therapeutics (FULC)

(Real Time Quote from BATS)

$9.03 USD

9.03
95,146

+0.43 (5.00%)

Updated Jul 23, 2024 11:24 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Oyster Point's (OYST) Tyrvaya Gets FDA Nod for Dry Eye Disease

by Zacks Equity Research

The FDA approves Oyster Point's (OYST) Tyrvaya nasal spray for the treatment of the signs and symptoms of dry eye disease.

    Can Fulcrum Therapeutics, Inc. (FULC) Climb 31% to Reach the Level Wall Street Analysts Expect?

    by Zacks Equity Research

    The consensus price target hints at a 30.9% upside potential for Fulcrum Therapeutics, Inc. (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

    Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 7.69% and 62.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    Will Fulcrum Therapeutics, Inc. (FULC) Report Negative Q2 Earnings? What You Should Know

    by Zacks Equity Research

    Fulcrum Therapeutics, Inc. (FULC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 18.18% and 119.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 12.33% and 153.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    Kodiak Sciences (KOD) Q3 Earnings Miss, KSI-301 in Focus

    by Zacks Equity Research

    Kodiak Sciences (KOD) reports wider-than-expected loss in the third quarter of 2020. The company is progressing well with the development of its lead pipeline candidate KSI-301.

    Novavax (NVAX) Loss Widens in Q3, Revenues Lag Estimates

    by Zacks Equity Research

    Novavax's (NVAX) bottom line deteriorates year over year in the third quarter of 2020. Revenues fall shy of estimates as well. Stock dips in after-hours trading.

    Fulcrum Therapeutics' (FULC) Shares March Higher, Can It Continue?

    by Zacks Equity Research

    As of late, it has definitely been a great time to be an investor in Fulcrum Therapeutics (FULC).

    Puma (PBYI) Down 8% on Q3 Earnings Lag, Nerlynx Sales View Cut

    by Zacks Equity Research

    Puma Biotech (PBYI) falls more than 8% as it misses on both earnings and revenues in the third quarter of 2020. The company trims its 2020 revenue guidance for Nerlynx.

    Why Fulcrum Therapeutics (FULC) Might Surprise This Earnings Season

    by Zacks Equity Research

    Fulcrum Therapeutics (FULC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Axsome's (AXSM) Q3 Earnings In Line, Pipeline Progresses

    by Zacks Equity Research

    Axsome (AXSM) earnings meet estimates in the third quarter. The company stretches the timeline for the NDA filing for AXS-05 and AXS-07. Shares fall.

    Editas' (EDIT) Earnings Rise Y/Y in Q3, EDIT-101 in Focus

    by Zacks Equity Research

    Editas' (EDIT) bottom line grows year over year in the third quarter while revenues beat estimates. Stock rises is after-hours trading.

    Agios' (AGIO) Q3 Loss Wider Than Expected, Revenues Miss

    by Zacks Equity Research

    Agios' (AGIO) earnings and revenues fall shy of estimates in the third quarter. The company lifts the lower end of 2020 sales guidance for its leukemia drug Tibsovo. Stock inches up.

    ACADIA (ACAD) Q3 Earnings Miss, Nuplazid Drives Revenues Y/Y

    by Zacks Equity Research

    ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid. Stock dips in after-hours trading.

    What's in the Cards for CVS Health (CVS) in Q3 Earnings?

    by Zacks Equity Research

    CVS Health's (CVS) Q3 earnings might have been affected by issues like lower prescription and soft front store volume due to decline in provider visits.

    National Vision (EYE) to Report Q3 Earnings: What's in Store?

    by Zacks Equity Research

    National Vision's (EYE) contact lens revenue growth is expected to have remained impressive in Q3 on lesser impact of store closures.

    Blueprint Medicines (BPMC) Q3 Earnings Beat, Revenues Rise Y/Y

    by Zacks Equity Research

    Blueprint Medicines' (BPMC) both bottom and the top line trump estimates in Q3. Ayvakit's sales rise sequentially.

    Why Earnings Season Could Be Great for Fulcrum Therapeutics (FULC)

    by Zacks Equity Research

    Fulcrum Therapeutics (FULC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Bionano (BNGO) to Report Q2 Earnings: What's in the Offing?

    by Zacks Equity Research

    Bionano's (BNGO) sales numbers will be in focus when it reports Q2 results later in the week.

    Kinjel Shah headshot

    5 Biotech Stocks Set to Outpace Q2 Earnings Estimates

    by Kinjel Shah

    Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.

    Fulcrum Therapeutics Sees Hammer Chart Pattern: Time to Buy?

    by Zacks Equity Research

    Fulcrum Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

    Is Fulcrum Therapeutics (FULC) Stock a Solid Choice Right Now?

    by Zacks Equity Research

    Fulcrum Therapeutics (FULC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

    Fulcrum Therapeutics, Inc. (FULC) Shares March Higher, Can It Continue?

    by Zacks Equity Research

    As of late, it has definitely been a great time to be an investor in Fulcrum Therapeutics, Inc. (FULC).

    Acceleron, Fulcrum Therapeutics Ink Deal for Pulmonary Disease

    by Zacks Equity Research

    Acceleron (XLRN) signs a collaboration/license pact with Fulcrum Therapeutics aimed at identifying small molecules designed to modulate specific pathways targeting a pulmonary disease indication.